ARVN 250516 10.00P(ARVN250516P10000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

ARVN250516P10000

Watchlist

0.90
+0.08+9.76%

15min DelayTrading Apr 30 11:08 ET

1.00High0.90Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaApr 30 08:07 ET
Earnings Preview: Arvinas to Report Financial Results on May 01
Moomoo NewsApr 28 08:45 ET
Arvinas Reports Preclinical Results for New Lymphoma Drug Combo at Cancer Research Meeting
BenzingaApr 28 06:47 ET
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
ArvinasApr 28 00:00 ET
Arvinas Announces Late-Breaking Oral Presentation of Phase 3 VERITAC-2 Trial Results for Vepdegestrant at ASCO 2025
Quiver QuantitativeApr 23 10:50 ET
Express News | Arvinas Announces Results From the Veritac-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (Asco) Annual Meeting
ReutersApr 23 10:44 ET

Comments

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual

$Arvinas (ARVN.US)$
Revolutionary Cancer Drug Shows Perfect Response Rate: Arvinas' ARV-393 Eliminates Tumors in Groundbreaking Study

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual

1

1

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

$Arvinas (ARVN.US)$
First Pivotal Data for Revolutionary Breast Cancer Drug to be Unveiled at ASCO 2025 Late-Breaking Session

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

$Arvinas (ARVN.US)$
Breakthrough Cancer Treatment ARV-393 Demonstrates Powerful Results Against Lymphoma in Latest Research

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

MMile Contractor

$Arvinas (ARVN.US)$ What happen bruh

2

2

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

$Arvinas (ARVN.US)$
First-Ever PROTAC Cancer Drug Hits Major Trial Milestone: What This Means

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

2

Read more